Get started

Dipbuy

APPLE ($AAPL): Should We Buy the Dip (if We Ever Get One)?✨ New charts every day ✨ Like, Comment & Follow to help the community grow 🎉🎉 --- Apple is coming off of good earnings and their new series of upcoming iPhones was just leaked (so far there seems to be a warm reception). With a strong uptrend and a monster of a company, it seems unwise to do anything other than look for a long position. With that in mind, one could argue the tech sector is a little overextended and running right into resistance here, not only is that true for the sector, it is also true for AAPL as well. The bet here is that despite tech and Apple being bullish overall, a pullback for Apple if not the whole sector is in the cards first. The goal would be to find an entry at support and ride this monster of tech back to resistance if not beyond to new all time highs. Resources: appleinsider.com + www.earningswhispers.com --- 1. Fractal Trend is showing a strong uptrend (Aqua bar color) on the 2 hour chart. The pullback to the S1 and S2 support levels should still be contained within the uptrend and not initiate a trend change (bar color change). 2. With this strategy, we we want to enter long on bullish order blocks plotted by Orderblock Mapping (Blue) and bullish S/R levels plotted by Directional Bias (Blue). 3. There are two really clear levels of resistance from the range formed in the earlier part of the year. We are looking at those Bearish levels (Red) to initiate a healthy correction to our S1 and S2 levels. 4. With that all in mind, we will exit positions if Fractal Trend changes color, at any point. This will help to lock in profits and limit risk if Apple can't retain its uptrend.
NASDAQ:AAPL
by AlphaBotSystem
3
Dip buy with a coronaThe Beijing branch of China’s National Health Commission said a combination of lopinavir and ritonavir, sold under the brand name Kaletra by AbbVie, is part of its latest treatment plan for patients infected by the Coronavirus, which has killed at 81 people in China and sickened more than 2,800 worldwide. After breaking out of the downtrend, ABBV is coming back to retest the channel, support area and weekly 50 moving average. In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 9. For comparison, its industry has an average Forward P/E of 15.48, which means ABBV is trading at a discount to the group. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be February 7, 2020. In that report, analysts expect ABBV to post earnings of $2.20 per share. This would mark year-over-year growth of 15.79%
NYSE:ABBVLong
by Charlestrad3r
Buy The Dip In $MYOK$MYOK has caught our attention after selling off on key data and bouncing off a key support level. Also, key data reported yesterday was positive. Here are the highlights: A 59-subject Phase 2 clinical trial, MAVERICK-HCM, evaluating MyoKardia's (NASDAQ:MYOK) mavacamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM) (the walls of the ventricles thicken compromising blood flow) met the primary endpoint of safety at week 16. Meaningful reductions in cardiac stress biomarkers were also noted. The results will be submitted for presentation at a future medical conference. The company intends to launch additional studies in patients with non-obstructive HCM (will provided a regulatory update in H1 2020) and heart failure with preserved ejection fraction (Phase 2 study should commence in Q2 2020). On another note, new data from its PIONEER open-label extension study of mavacemten in symptomatic obstructive HCM showed consistent results at week 48 (12 participants) compared to weeks 12, 24 and 36. Shares closed down 7% after the 5% runup at the end of last week. MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California. As always, trade with caution and use protective stops. Good luck to all!
MLong
by InsiderFinancial
Get Ready To Buy The Dip In $CGC$CGC has been been beaten up like the rest of the pot sector. However, $CGC is different in that the company has $13/share in cash. While we aren't calling a bottom yet, investors should start preparing themselves to buy the dip in $CGC. Canopy Growth Corporation, together with its subsidiaries, engages in engages in production, distribution, and sale of cannabis in Canada. It operates through two segments, Cannabis Operations and Canopy Rivers. The company’s products include dried flowers, oils and concentrates, softgel capsules, and hemps. It offers its products under the Tweed, Spectrum, DNA Genetics, CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Maitri brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada to investigate the efficacy of cannabinoids for the treatment of post-concussion neurological diseases in former NHL players; partnership with Parent Action on Drugs; and a collaboration with Cure Pharmaceutical Holding Corp. for the development of low-dose cannabidiol oral thin films. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada. As always, trade with caution and use protective stops. Good luck to all!
CLong
by InsiderFinancial
ROST t.a. & set upROST price is showing signs of an overall uptrend pattern long term, consistently making higher highs and higher lows. Price also trades above the SMA200, indicating potential bullish movement. Price seems to react best with EMA/SMA levels on the 4 hr chart. Price just broke above EMA10, and SMA100 today, also the last candle stick formed a Long Bullish Candle, as well as extremely oversold RSI levels @30. Strong convergence of combined signals now indicating bullish momentum likely to continue. A good swing trade entry might be: only if price breaks above AND closes above both the EMA10 and SMA50 (4 hour chart) around or above 107.84 level by end of day close A stop could be set: 106.74 @ -1% Exit could be: 110 area @ +3% Risk/Reward ratio favorable @ 3:1
NASDAQ:ROSTLong
by gaaragaara
Short term Analysis - BTC to 13k but then what?COINBASE:BTCUSD is currently in a descending parallel channel, but has a nice support on 10.5 k (2.27 on fib) so once the parallel channel squeezes near the support BTC should be going up again. But then what? It will hit a 13 k (3.27 on fib) resistance, will it have enough momentum to break through? All sorts of news outlets are reporting on BTC so, once the price gets going again, we should have a FOMO fueling the rally. If we break the 13 k resistance I think we might see prices as high as 15.5 k (4.27 on fib). So I would buy the dip gradually between 10.75 and 10.5 k with stop loss at 10.1 k On the other hand, if the down trend channel breaks the 10.5 k support, than I regret to say that this bull run is probably over. The "good news"? We'll have support at 8.8 k and 7.5 k. PS: I'm quite new to trading and this is my first published analysis - Please give feedback so I can improve and learn from your insight :)
COINBASE:BTCUSDLong
by AureateDominus
BTC Update! Bear flag break and strong dip buying!Leaving same 4 hour chart from yesterday here and if you actually zoom in on smaller time frame (5-15 minutes) it is much clearer. But yesterday we were watching for a potential bear flag as well as watching our 12 EMA serve as resistance. The bears made an initial bear break but overall was fairly weak and a fairly quick recovery by the bulls to buy things back up. Bulls were again rejected by the 12 EMA tho and then the real bear break began where the bears crashed through some prior lows. Bulls did give an extremely strong buying of the dip and this bear break lasted all of 5-10 minutes going down to $3425 before rebounding. Bulls made a decent attempt here to break to a new high for the past 48 hours and go ahead of 12 EMA and tried to get ahead of 26 EMA as well. Currently bears have stepped back in but bulls fighting to maintain 12 EMA as support here which would be great news if they managed to pull that off. Zooming out towards daily and bulls have anything under $3766 is just another lower high. $3425 is currently our lower low on the daily as the bears seek to stair step the price action back down towards $3k. While I am not excited to jump into a bullish position, I am happy to see the bulls not just rolling over and letting the bears take full control. Bulls are stepping in to buy these dips but if they continue to only set lower highs and then lower lows on our daily, it just becomes a matter of time before the bears make their big push. So stay cautious, if anyone played the dip buy early this morning, it gave a nice 4-4.5% return in minutes. Just My 2 Sats!
COINBASE:BTCUSD
by My2Sats
EURUSD dip buyers retain controlThe euro currency is starting to recover short-term bullish momentum against the US dollar, following a brief test of buying demand below the key 1.1490 level. The intraday sentiment surrounding the EURUSD pair remains bullish while price trades above the 1.1490. It is also worth noting that the EURUSD has performed two consecutive daily price closes above its one-hundred day moving average. The EURUSD pair is intraday bullish while trading above the 1.1490 level, key technical resistance remains at the 1.1550 and 1.1600 levels. If the EURUSD pair moves below the 1.1490 level, sellers may test towards the 1.1460 and 1.1430 support levels.
by OctaFX_Official